A5089012331- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Breast Cancer Treatment Studies
- Renal cell carcinoma treatment
- Radiation Therapy and Dosimetry
- Hematopoietic Stem Cell Transplantation
- Urologic and reproductive health conditions
- Lung Cancer Diagnosis and Treatment
- Polyomavirus and related diseases
- Bladder and Urothelial Cancer Treatments
- Functional Brain Connectivity Studies
- Meningioma and schwannoma management
- MRI in cancer diagnosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Effects of Radiation Exposure
- COVID-19 and healthcare impacts
- Oral health in cancer treatment
- Spine and Intervertebral Disc Pathology
University of Perugia
2019-2025
University of Rome Tor Vergata
2008-2019
Policlinico Tor Vergata
2008-2019
Ludwig-Maximilians-Universität München
2019
LMU Klinikum
2019
Azienda Ospedaliero-Universitaria di Modena
2016
Herlev Hospital
2016
University of Copenhagen
2016
Università Campus Bio-Medico
2016
Expert System (Italy)
2016
PURPOSE ARTO (ClinicalTrials.gov identifier: NCT03449719 ) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS All were affected by CRPC as defined three or less nonvisceral metastatic lesions. Patients randomly assigned 1:1 receive either AAP alone (control arm) concomitant SBRT...
The aim of the present study is to evaluate impact metastases-directed stereotactic body radiotherapy in two groups oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant (oligo-CRPC). Inclusion criteria multicentre retrospective analysis were: (1) PC, defined as presence 1–3 lesions (bone or nodes) detected with choline positron emission tomography CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, metastases after a...
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed 2 remaining major unmet medical needs: relapse and chronic graft-versus-host disease (cGVHD). Fifty AML patients were enrolled study. The conditioning regimen included total body irradiation for up to age 50 years marrow/lymphoid 51 65 years. Irradiation was...
Background and purposeOligometastatic prostate cancer is a new emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective small phase 2 large difference across centers. Pending results ongoing trials, there clear need for more consistent indications radiotherapy practices.Material methodsA European Society...
To identify predictive factors of radiation-induced skin toxicity in breast cancer patients by the analysis dosimetric and clinical factors.339 treated between January 2007 December 2010 are included present analysis. Whole irradiation was delivered with Conventional Fractionation (CF) (50 Gy, 2.0/day, 25 fractions) moderate Hypofractionated Schedule (HS) (44 2.75 Gy/day, 16 followed tumour bed boost. The impact patient features, systemic treatments and, particular, dose inhomogeneities on...
397 Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic body radiotherapy (SBRT) administration in oligometastatic castrate resistant prostate cancer patients (omCRPC). Both biochemical response progression free survival (bPFS) were improved by addition SBRT experimental arm if compared to abiraterone alone. Here is presented secondary analysis focusing on prognostic impact BRCA alterations...
160 Background: Apalutamide+androgen deprivation therapy (ADT) showed to significantly improve overall survival in low and high volume metastatic hormone sensitive prostate cancer (mHSPC) if compared ADT alone. However, a randomized phase II trial (ARTO, NCT03449719) suggested that stereotactic body radiotherapy (SBRT) improved clinical outcomes when administered concomitantly with abiraterone acetate castration resistance (mCRPC). Nonetheless, evidence related use of SBRT addition androgen...
Abstract Background Moderate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on results randomized prospective trials, but there clinical concern about relatively short length follow-up, and real-world outcome toxicity cutting-edge techniques are lacking. The objective this study to present long-term large multicentric series. Materials methods We retrospectively evaluated 1325 PCa treated with daily volumetric image-guided...
Background/Aim: This multicenter, retrospective, ‘field-practice’ study investigated treatment outcomes of ongoing abiraterone therapy with the addition radiotherapy (RT) – initiated for oligoprogression or a palliative intent. Patients and Methods: Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated acetate were considered if they had received RT after initiation treatment. Results: A total 32 enrolled in study. Median duration was 13.0 months...